Grufity logoGrufity logo
StocksFundsSearch Filings

Arcutis Biotherapeutics, Inc. Stock Research

ARQT

7.30USD-0.51(-6.53%)Delayedas of 31 May 2023, 01:12 pm

Market Summary

USD7.30-0.51
Delayedas of 31 May 2023, 01:12 pm
-6.53%

ARQT Stock Price

ARQT RSI Chart

ARQT Valuation

Market Cap

479.2M

Price/Earnings (Trailing)

-1.46

Price/Sales (Trailing)

55.58

Price/Free Cashflow

-1.7

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

79.54%

Return on Equity

-148.61%

Return on Assets

-69.32%

Free Cashflow Yield

-58.72%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

8.6M

ARQT Earnings

Earnings (TTM)

-327.2M

Earnings Y/Y

-24.53%

Earnings Q/Q

-11.22%

Price Action

52 Week Range

7.2527.40
(Low)(High)

Last 7 days

-17.5%

Last 30 days

-43.6%

Last 90 days

-53.2%

Trailing 12 Months

-62.8%

ARQT Financial Health

Current Ratio

11.57

Debt/Equity

0.94

Debt/Cashflow

-1.31

ARQT Investor Care

Shares Dilution (1Y)

19.47%

Diluted EPS (TTM)

-5.65

Peers (Alternatives to Arcutis Biotherapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
116.8B
26.2B
-8.85% -12.37%
14.75
4.46
-0.48% 38.34%
95.3B
27.0B
-7.15% 22.78%
17.06
3.52
-1.56% 23.65%
49.5B
15.1B
-3.01% -12.71%
10.35
3.29
-33.37% -67.32%
43.1B
10.1B
-1.82% 44.85%
13.78
4.27
-6.61% 115.98%
MID-CAP
8.8B
1.6B
-10.82% -3.21%
137.28
5.5
32.38% -10.36%
4.0B
-
17.83% 16.01%
-10.8
36.9
122.90% -29.67%
2.4B
76.7M
3.87% -11.56%
-7.51
30.96
41.73% -32.75%
2.2B
107.9M
-6.75% 87.02%
-4.48
20.12
54.84% 17.36%
SMALL-CAP
1.5B
119.0M
13.50% 5.58%
-5.31
12.45
-69.61% -584.39%
1.1B
10.0M
10.82% 23.60%
-6.03
105.01
215.65% -47.65%
641.1M
-
-3.13% -86.56%
-0.55
0.32
72.89% 12.32%
487.0M
136.9M
-18.29% -78.97%
-2.07
3.56
116.83% -0.93%
191.0M
241.0M
-22.11% -68.89%
-1.5
0.79
113.96% 27.87%
166.8M
697.0K
51.20% -67.02%
-1.55
239.29
47.98% -35.48%
9.0M
-
-32.41% -88.55%
-0.12
3.21
0.51% -129.47%

Financials for Arcutis Biotherapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q1
Revenue133.9%8,622,6673,686,000-
Operating Expenses5.4%321,731,000305,313,000305,214,000233,072,000-
  S&GA Expenses17.6%122,124,000103,829,00068,523,000--
  R&D Expenses-2.9%177,158,000182,435,000201,116,000164,549,000-
Interest Expenses33.2%20,856,00015,652,0008,737,0001,838,000-
Net Income-5.1%-327,234,000-311,458,000-310,765,000-234,638,000-
Net Income Margin21.1%-84.50-107---
Free Cahsflow-8.0%-258,048,000-238,830,000-185,964,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-15.5%379449509300364
  Current Assets-15.9%368437497295359
    Cash Equivalents53.5%82.0054.0082.0062.0070.00
  Inventory13.8%9.008.004.00--
  Net PPE10.0%2.002.002.002.002.00
Liabilities0.0%240240238105110
  Current Liabilities-2.1%37.0038.0037.0027.0033.00
  Long Term Debt169.0%19773.0073.00--
    LT Debt, Non Current0.5%19919819773.0073.00
Shareholder's Equity-33.3%140210271195254
  Retained Earnings-11.1%-799-719-647-540-472
  Additional Paid-In Capital1.0%940930920737727
Accumulated Depreciation18.8%1.001.001.00--
Shares Outstanding0.5%61.0061.0061.0052.0051.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-9.1%-281-257-238-211-185
  Share Based Compensation9.0%36.0033.0029.0026.0022.00
Cashflow From Investing106.0%5.00-87.20-10595.00-122
Cashflow From Financing-4.8%28730237489.0089.00

Risks for ARQT

What is the probability of a big loss on ARQT?

94.9%


Probability that Arcutis Biotherapeutics stock will be more than 20% underwater in next one year

81.7%


Probability that Arcutis Biotherapeutics stock will be more than 30% underwater in next one year.

68%


Probability that Arcutis Biotherapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARQT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcutis Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ARQT

Cumulative Returns on ARQT

-38.5%


3-Year Cumulative Returns

Which funds bought or sold ARQT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
sold off
-100
-153,609
-
-%
2023-05-22
AMERIPRISE FINANCIAL INC
added
5.05
-2,639,930
9,402,070
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-19.98
-179,000
264,000
-%
2023-05-18
JPMORGAN CHASE & CO
added
23.38
-55,000
605,000
-%
2023-05-17
Thrivent Financial for Lutherans
unchanged
-
-129,000
373,000
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-1,653
4,785
-%
2023-05-16
JANE STREET GROUP, LLC
new
-
288,805
288,805
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
376
839,824
1,169,890
-%
2023-05-16
SRS Capital Advisors, Inc.
added
23.53
-41.00
462
-%
2023-05-15
Balyasny Asset Management L.P.
new
-
487,168
487,168
-%

1–10 of 43

Latest Funds Activity

Are funds buying ARQT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ARQT
No. of Funds

Arcutis Biotherapeutics News

msnNOW
Stocks That Hit 52-Week Lows On Tuesday.
msnNOW,
23 hours ago
InvestorPlace
Investing.com UK

Schedule 13G FIlings of Arcutis Biotherapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
point72 asset management, l.p.
1.8%
1,103,576
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 08, 2023
state street corp
6.04%
3,679,385
SC 13G
Feb 03, 2023
blackrock inc.
8.6%
5,214,258
SC 13G/A
Aug 26, 2022
orbimed advisors llc
4.7%
2,828,356
SC 13D/A
Jun 28, 2022
orbimed advisors llc
6.9%
3,534,537
SC 13D/A
May 27, 2022
bain capital life sciences fund, l.p.
5.3%
2,721,436
SC 13D/A
Apr 08, 2022
orbimed advisors llc
7.6%
3,840,564
SC 13D/A
Feb 14, 2022
point72 asset management, l.p.
5.3%
2,644,177
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

ARQT Fair Value

Show Fair-Value

Recent SEC filings of Arcutis Biotherapeutics

View All Filings
Date Filed Form Type Document
May 24, 2023
8-K
Current Report
May 09, 2023
10-Q
Quarterly Report
May 09, 2023
8-K
Current Report
Apr 18, 2023
4
Insider Trading
Apr 18, 2023
DEF 14A
DEF 14A
Apr 18, 2023
DEFA14A
DEFA14A
Apr 17, 2023
144
Notice of Insider Sale Intent
Apr 10, 2023
4
Insider Trading
Mar 31, 2023
4/A
Insider Trading
Mar 08, 2023
4
Insider Trading

Latest Insider Trading transactions for ARQT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-17
Welgus Howard G.
sold
-118,728
13.968
-8,500
-
2023-04-17
Welgus Howard G.
acquired
14,285
1.6806
8,500
-
2023-04-06
Welgus Howard G.
acquired
14,285
1.6806
8,500
-
2023-04-06
Welgus Howard G.
sold
-102,085
12.01
-8,500
-
2023-03-06
Watanabe Todd Franklin
sold
-37,167
15.2638
-2,435
see remarks
2023-03-06
Burrows Scott L
sold
-4,441
15.2634
-291
chief financial officer
2023-03-06
OSBORNE DAVID W
sold
-10,531
15.2634
-690
chief technical officer
2023-03-06
Burnett Patrick
sold
-12,989
15.2634
-851
see remarks
2023-03-06
Lock Kenneth A.
sold
-12,684
15.2636
-831
chief commercial officer
2023-03-06
Turney Patricia A.
sold
-12,684
15.2635
-831
svp, operations

1–10 of 50

Todd F. Watanabe
150
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Income Statement

2023-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Revenue, Product and Service [Extensible Enumeration]Product [Member]Product [Member]
Total revenues$ 2,781$ 0
Operating expenses:  
Cost of sales7830
Research and development35,34540,622
Selling, general, and administrative42,91822,006
Total operating expenses79,04662,628
Loss from operations(76,265)(62,628)
Other income (expense):  
Other income, net3,207142
Interest expense(7,042)(1,838)
Total other income (expense)(3,835)(1,696)
Other comprehensive income (loss):  
Unrealized income (loss) on marketable securities724(765)
Foreign currency translation adjustment(52)0
Total other comprehensive income (loss)672(765)
Net loss(80,100)(64,324)
Comprehensive loss$ (79,428)$ (65,089)
Per share information:  
Net loss per share, basic (in USD per share)$ (1.31)$ (1.27)
Net loss per share, diluted (in USD per share)$ (1.31)$ (1.27)
Weighted-average shares used in computing net loss per share, basic (in shares)61,169,08950,513,524
Weighted-average shares used in computing net loss per share, diluted (in shares)61,169,08950,513,524

ARQT Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 81,405$ 53,641
Restricted cash9251,234
Trade receivables, net12,7698,458
Marketable securities251,000355,948
Inventories8,5517,514
Prepaid expenses and other current assets13,02610,611
Total current assets367,676437,406
Property, plant, and equipment, net2,0701,881
Intangible assets, net7,0007,188
Operating lease right-of-use asset2,6342,721
Other assets7878
Total assets379,458449,274
Current liabilities:  
Accounts payable12,4858,827
Accrued liabilities23,86428,323
Operating lease liability676657
Total current liabilities37,02537,807
Operating lease liability, noncurrent3,9384,117
Long-term debt, net198,763197,769
Total liabilities239,726239,693
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022;00
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2023 and December 31, 2022; 61,369,061 and 61,052,250 shares issued at March 31, 2023 and December 31, 2022, respectively; 61,357,932 and 61,037,403 shares outstanding at March 31, 2023 and December 31, 2022, respectively66
Additional paid-in capital940,004930,425
Accumulated other comprehensive loss(414)(1,086)
Accumulated deficit(799,864)(719,764)
Total stockholders’ equity139,732209,581
Total liabilities and stockholders’ equity$ 379,458$ 449,274